DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
10647
ML-246
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ML-246
×
Maximum Phase:
1
First Approval:
None
UNII:
Q6A9F9DSX5
Molecule Type:
Small molecule
Molecular Formula:
C31H30N4O
Molecular Weight:
474.61
AlogP:
6.18
PSA:
66.83
HBD:
2.0
HBA:
#RotB:
5.0
Source:
TNB-486
1
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
TNB-486
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
AZD-1208
1
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute; Lymphoma; Neoplasms
Serine/threonine-protein kinase PIM inhibitor
AZD-1208
×
Maximum Phase:
1
First Approval:
None
UNII:
S98NFM1378
Molecule Type:
Small molecule
Molecular Formula:
C21H21N3O2S
Molecular Weight:
379.49
AlogP:
3.61
PSA:
75.43
HBD:
2.0
HBA:
#RotB:
3.0
Source:
BISTHIANOSTAT
1
Small molecule
Investigational
Unknown
Unknown
Multiple Myeloma
Unknown
BISTHIANOSTAT
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C15H18N4O3S2
Molecular Weight:
366.47
AlogP:
2.55
PSA:
104.21
HBD:
3.0
HBA:
#RotB:
8.0
Source:
TALINOLOL
1
Small molecule
Investigational
Unknown
Unknown
Cardiovascular Diseases; Obesity, Morbid
Unknown
TALINOLOL
×
Maximum Phase:
1
First Approval:
None
UNII:
3S82268BKG
Molecule Type:
Small molecule
Molecular Formula:
C20H33N3O3
Molecular Weight:
363.5
AlogP:
3.27
PSA:
82.62
HBD:
4.0
HBA:
#RotB:
7.0
Source:
ATIPAMEZOLE
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ATIPAMEZOLE
×
Maximum Phase:
1
First Approval:
None
UNII:
03N9U5JAF6
Molecule Type:
Small molecule
Molecular Formula:
C14H16N2
Molecular Weight:
212.3
AlogP:
2.86
PSA:
28.68
HBD:
1.0
HBA:
#RotB:
2.0
Source:
OLVIMULOGENE NANIVACIREPVEC
1
Gene
Investigational
Unknown
Unknown
Head and Neck Neoplasms; Lung Neoplasms; Neoplasms
Unknown
OLVIMULOGENE NANIVACIREPVEC
×
Maximum Phase:
1
First Approval:
None
UNII:
CF19SF72O5
Molecule Type:
Gene
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMC-EB10
1
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid
Tyrosine-protein kinase receptor FLT3 inhibitor
IMC-EB10
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LBY-135
1
Antibody
Investigational
Unknown
Unknown
Unknown
Tumor necrosis factor receptor superfamily member 10B agonist
LBY-135
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VORSETUZUMAB MAFODOTIN
1
Antibody
Investigational
Unknown
Unknown
Carcinoma, Renal Cell
CD70 antigen binding agent
VORSETUZUMAB MAFODOTIN
×
Maximum Phase:
1
First Approval:
None
UNII:
699619YVTQ
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
REBAUDIOSIDE A
1
Oligosaccharide
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
REBAUDIOSIDE A
×
Maximum Phase:
1
First Approval:
None
UNII:
B3FUD0528F
Molecule Type:
Oligosaccharide
Molecular Formula:
C44H70O23
Molecular Weight:
967.02
AlogP:
-5.11
PSA:
374.13
HBD:
14.0
HBA:
#RotB:
12.0
Source:
ELTANEXOR
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ELTANEXOR
×
Maximum Phase:
1
First Approval:
None
UNII:
Q59IQJ9NTK
Molecule Type:
Small molecule
Molecular Formula:
C17H10F6N6O
Molecular Weight:
428.3
AlogP:
3.26
PSA:
99.58
HBD:
1.0
HBA:
#RotB:
4.0
Source:
MDX-1342
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell
B-lymphocyte antigen CD19 binding agent
MDX-1342
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GSK-1614235
1
Unknown
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
GSK-1614235
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RO6895882
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
RO6895882
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MK-8245
1
Small molecule
Investigational
Unknown
Unknown
Diabetes Mellitus, Type 2
Unknown
MK-8245
×
Maximum Phase:
1
First Approval:
None
UNII:
537E7QE8LX
Molecule Type:
Small molecule
Molecular Formula:
C17H16BrFN6O4
Molecular Weight:
467.26
AlogP:
2.36
PSA:
119.4
HBD:
1.0
HBA:
#RotB:
6.0
Source:
SIZOFIRAN
1
Unknown
Investigational
Unknown
Unknown
Uterine Cervical Neoplasms
Unknown
SIZOFIRAN
×
Maximum Phase:
1
First Approval:
None
UNII:
7F763NNC9X
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MCAF5352A
1
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
MCAF5352A
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IRSOGLADINE
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
IRSOGLADINE
×
Maximum Phase:
1
First Approval:
None
UNII:
QBX79NZC1D
Molecule Type:
Small molecule
Molecular Formula:
C9H7Cl2N5
Molecular Weight:
256.1
AlogP:
2.01
PSA:
90.71
HBD:
2.0
HBA:
#RotB:
1.0
Source:
RX-3117
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
RX-3117
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TUROFEXORATE ISOPROPYL
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Bile acid receptor FXR agonist
TUROFEXORATE ISOPROPYL
×
Maximum Phase:
1
First Approval:
None
UNII:
S6KDM312I5
Molecule Type:
Small molecule
Molecular Formula:
C25H24F2N2O3
Molecular Weight:
438.47
AlogP:
5.17
PSA:
62.4
HBD:
1.0
HBA:
#RotB:
3.0
Source:
AVACINCAPTAD PEGOL SODIUM
1
Unknown
Investigational
Unknown
Unknown
Macular Degeneration
Unknown
AVACINCAPTAD PEGOL SODIUM
×
Maximum Phase:
1
First Approval:
None
UNII:
K86ENL12I5
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PERAKIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Arthritis, Psoriatic
Interleukin 17A inhibitor
PERAKIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
867X5909JO
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LETRAZURIL
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LETRAZURIL
×
Maximum Phase:
1
First Approval:
None
UNII:
U8736VCB22
Molecule Type:
Small molecule
Molecular Formula:
C17H9Cl2FN4O2
Molecular Weight:
391.19
AlogP:
3.02
PSA:
91.54
HBD:
1.0
HBA:
#RotB:
3.0
Source:
BIO89-100
1
Unknown
Investigational
Unknown
Unknown
Hypertriglyceridemia; Non-alcoholic Fatty Liver Disease
Unknown
BIO89-100
×
Maximum Phase:
1
First Approval:
None
UNII:
UO870O6MFS
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MDM2
1
Unknown
Investigational
Unknown
Unknown
Unknown
Unknown
MDM2
×
Maximum Phase:
1
First Approval:
None
UNII:
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TERGENPUMATUCEL-L
1
Cell
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung
Unknown
TERGENPUMATUCEL-L
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Cell
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
RG-7795
1
Unknown
Investigational
Unknown
Unknown
Hepatitis C
Unknown
RG-7795
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Unknown
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UNESBULIN
1
Small molecule
Investigational
Unknown
Unknown
Diffuse Intrinsic Pontine Glioma; Leiomyosarcoma; Neoplasms; Ovarian Neoplasms
Unknown
UNESBULIN
×
Maximum Phase:
1
First Approval:
None
UNII:
Z4HZ70S62Q
Molecule Type:
Small molecule
Molecular Formula:
C19H13F5N6
Molecular Weight:
420.35
AlogP:
4.75
PSA:
81.65
HBD:
2.0
HBA:
#RotB:
3.0
Source:
NANATINOSTAT
1
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Unknown
NANATINOSTAT
×
Maximum Phase:
1
First Approval:
None
UNII:
YTL7A418KQ
Molecule Type:
Small molecule
Molecular Formula:
C20H19FN6O2
Molecular Weight:
394.41
AlogP:
1.51
PSA:
103.27
HBD:
3.0
HBA:
#RotB:
5.0
Source:
SELITRECTINIB
1
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Neurotrophic tyrosine kinase receptor inhibitor
SELITRECTINIB
×
Maximum Phase:
1
First Approval:
None
UNII:
0J45910S3X
Molecule Type:
Small molecule
Molecular Formula:
C20H21FN6O
Molecular Weight:
380.43
AlogP:
2.67
PSA:
75.42
HBD:
1.0
HBA:
#RotB:
0.0
Source:
TAK-915
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
TAK-915
×
Maximum Phase:
1
First Approval:
None
UNII:
0M4DME62Y9
Molecule Type:
Small molecule
Molecular Formula:
C19H18F4N4O5
Molecular Weight:
458.37
AlogP:
2.98
PSA:
102.02
HBD:
2.0
HBA:
#RotB:
6.0
Source:
HYDROXYNORKETAMINE, (2R,6R)
1
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
HYDROXYNORKETAMINE, (2R,6R)
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C12H14ClNO2
Molecular Weight:
239.7
AlogP:
1.61
PSA:
63.32
HBD:
2.0
HBA:
#RotB:
1.0
Source:
CEDELIZUMAB
1
Antibody
Investigational
Unknown
Unknown
Unknown
T-cell surface antigen CD4 inhibitor
CEDELIZUMAB
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FARLETUZUMAB ECTERIBULIN
1
Antibody
Investigational
Unknown
Unknown
Neoplasms
Unknown
FARLETUZUMAB ECTERIBULIN
×
Maximum Phase:
1
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
86
87
88
89
90
91
92
…
304
305
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA